3.0
Jan 12, 2024
Former employee, more than 1 year
Framingham, MA
Recommend
CEO approval
Business Outlook
Pros
Great pipeline, average benefits for the biopharma industry
Cons
Slow and bureaucratic, they try and make things less complicated by complicating them more and there seems to be no end to this cycle.